Literature DB >> 22644164

Sinus venous stenosis, intracranial hypertension and progression of primary headaches.

Roberto De Simone1, Angelo Ranieri, Silvana Montella, Mario Marchese, Pasquale Persico, Vincenzo Bonavita.   

Abstract

The recently advanced hypothesis that idiopathic intracranial hypertension without papilledema (IIHWOP) is a powerful risk factor for the progression of pain in individuals prone to episodic primary headache implies that IIHWOP is much more prevalent than it is believed to be in the general population and that it can run almost asymptomatic in most of the affected individuals. In this review, we discuss the evidence available supporting that: (a) sinus venous stenosis-associated IIHWOP is much more prevalent than believed in the general population and can run without symptoms or signs of raised intracranial pressure in most of individuals affected, (b) sinus venous stenosis is a very sensitive and specific predictor of intermittent or continuous idiopathic intracranial hypertension with or without papilledema, even in asymptomatic individuals, (c) in primary headache prone individuals, a comorbidity with a hidden stenosis-associated IIHWOP represents a very common, although largely underestimated, modifiable risk factor for the progression and refractoriness of headache.

Entities:  

Mesh:

Year:  2012        PMID: 22644164     DOI: 10.1007/s10072-012-1037-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  49 in total

1.  Abnormal pressure waves in headache sufferers with bilateral transverse sinus stenosis.

Authors:  F Bono; D Salvino; T Tallarico; D Cristiano; F Condino; F Fera; Pl Lanza; A Lavano; A Quattrone
Journal:  Cephalalgia       Date:  2010-05-12       Impact factor: 6.292

2.  Coupling of sagittal sinus pressure and cerebrospinal fluid pressure in idiopathic intracranial hypertension--a preliminary report.

Authors:  J D Pickard; Z Czosnyka; M Czosnyka; B Owler; J N Higgins
Journal:  Acta Neurochir Suppl       Date:  2008

3.  Intracranial venous sinus stenting for benign intracranial hypertension: clinical indications, technique, and preliminary results.

Authors:  Felipe C Albuquerque; Shervin R Dashti; Yin C Hu; C Benjamin Newman; Mohamed Teleb; Cameron G McDougall; Harold L Rekate
Journal:  World Neurosurg       Date:  2011 May-Jun       Impact factor: 2.104

4.  New daily persistent headache: should migrainous features be incorporated?

Authors:  Kuan-Po Peng; Jong-Ling Fuh; Hsiang-Kuo Yuan; Ben-Chang Shia; Shuu-Jiun Wang
Journal:  Cephalalgia       Date:  2011-09-29       Impact factor: 6.292

5.  Obesity is a risk factor for transformed migraine but not chronic tension-type headache.

Authors:  Marcelo E Bigal; Richard B Lipton
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

6.  Topiramate as an inhibitor of carbonic anhydrase isoenzymes.

Authors:  S J Dodgson; R P Shank; B E Maryanoff
Journal:  Epilepsia       Date:  2000       Impact factor: 5.864

7.  Bilateral transverse sinus stenosis and idiopathic intracranial hypertension without papilledema in chronic tension-type headache.

Authors:  F Bono; D Messina; C Giliberto; D Cristiano; G Broussard; S D'Asero; F Condino; L Mangone; C Mastrandrea; F Fera; A Quattrone
Journal:  J Neurol       Date:  2008-05-06       Impact factor: 4.849

8.  Idiopathic intracranial hypertension with and without papilloedema in a consecutive series of patients with chronic migraine.

Authors:  D S S Vieira; M R Masruha; A L Gonçalves; E Zukerman; C A Senne Soares; M da Graça Naffah-Mazzacoratti; M F P Peres
Journal:  Cephalalgia       Date:  2008-03-31       Impact factor: 6.292

9.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292

10.  Transformed migraine.

Authors:  N T Mathew
Journal:  Cephalalgia       Date:  1993-04       Impact factor: 6.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.